DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Reichardt P, Blay JY, Gelderblom H et al.
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Ann Oncol 2012;
23: 1680-1687
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.